Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

被引:36
作者
Ma, B. B. Y. [1 ,7 ]
Goh, B. C. [2 ]
Lim, W. T. [3 ]
Hui, E. P. [1 ]
Tan, E. H. [3 ]
Lopes, G. de Lima [4 ]
Lo, K. W. [5 ]
Li, L. [1 ]
Loong, H. [1 ]
Foster, N. R. [6 ]
Erlichman, C. [6 ]
King, A. D. [8 ]
Kam, M. K. M. [7 ]
Leung, S. F. [7 ]
Chan, K. C. [9 ]
Chan, A. T. C. [1 ]
机构
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Sir YK Pao Ctr Canc, State Key Lab Oncol South China, Shatin, Hong Kong, Peoples R China
[2] Natl Univ Singapore Hosp, Canc Sci Inst Singapore, Singapore, Singapore
[3] Singhealth, Natl Canc Ctr Singapore, Invest Med Unit, Singapore, Singapore
[4] Johns Hopkins Singapore Int Med Ctr, Singapore, Singapore
[5] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China
[6] Mayo Clin, Rochester, MN USA
[7] Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[8] Chinese Univ Hong Kong, Dept Radiol, Shatin, Hong Kong, Peoples R China
[9] Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China
关键词
AKT inhibitor; MK2206; PIK3CA; Nasopharyngeal carcinoma; BARR-VIRUS DNA; BREAST-CANCER; PRECLINICAL EVALUATION; PI3K PATHWAY; EBV DNA; PLASMA; BIOMARKERS; PIK3CA; SENSITIVITY; RESISTANCE;
D O I
10.1007/s10637-015-0264-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study investigated the activity of MK-2206, an AKT inhibitor, in metastatic or recurrent nasopharyngeal carcinoma (NPC). Method Oral MK-2206 at a dose of 200 mg was administered on days 1, 8, 15 and 22 of a 28-day cycle until progression. Plasma EBV DNA clearance during the first month of treatment was measured, and archived tumors were analyzed for the expression of AKT and PIK3CA mutation and PIK3CA amplification. The dual primary endpoint was objective response rate and 6-month progression-free survival (PFS) rate. Results 21 patients were enrolled and one patient achieved a partial response (5 %) and 11 had stable disease (52 %), with a median PFS of 3.5 months (95 % confidence interval, CI: 0.9-7.3). The 6-month PFS rate was 43 % (95 % CI: 22-66 %) and the median OS was 10 months (95 % CI: 5.9 months-not reached). Seven patients (33 %) experienced grade 3 toxicities which could be related to MK-2206. Macular-papular rash was the most common (n = 6), followed by hyperglycemia (n = 2) and fatigue (n = 1). In the 12 tumor samples analyzed, PIK3CA amplification was detected in one patient's primary NPC, who had SD lasting over 12 months. Patients with decreasing EBV DNA values over time were more likely to be alive and progression-free for at least 6 months than those without a decrease (p = 0.001). Conclusion The study was terminated due to the limited activity observed in this heavily pre-treated group of patients. Further studies are needed to elucidate the optimal way of selecting patients for AKT inhibitors.
引用
收藏
页码:985 / 991
页数:7
相关论文
共 35 条
[1]   PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System [J].
Beaver, Julia A. ;
Gustin, John P. ;
Yi, Kyung H. ;
Rajpurohit, Anandita ;
Thomas, Matthew ;
Gilbert, Samuel F. ;
Rosen, D. Marc ;
Park, Ben Ho ;
Lauring, Josh .
CLINICAL CANCER RESEARCH, 2013, 19 (19) :5413-5422
[2]  
Chan ATC, 2002, JNCI-J NATL CANCER I, V94, P1614, DOI 10.1093/jnci/94.21.1614
[3]   Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma [J].
Chan, ATC ;
Hsu, MM ;
Goh, BC ;
Hui, EP ;
Liu, TW ;
Millward, MJ ;
Hong, RL ;
Whang-Peng, J ;
Ma, BBY ;
To, KF ;
Mueser, M ;
Amellal, N ;
Lin, X ;
Chang, AY .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3568-3576
[4]  
Chan KCA, 2003, CANCER RES, V63, P2028
[5]   Nasopharyngeal carcinoma - Review of the molecular mechanisms of tumorigenesis [J].
Chou, Josephine ;
Lin, Yu-Ching ;
Kim, Jae ;
You, Liang ;
Xu, Zhidong ;
He, Biao ;
Jablons, David M. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (07) :946-963
[6]   PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma [J].
Fendri, Ali ;
Khabir, Abdelmajid ;
Mnejja, Wafa ;
Sellami-Boudawara, Tahia ;
Daoud, Jamel ;
Frikha, Mounir ;
Ghorbel, Abdelmonem ;
Gargouri, Ali ;
Mokdad-Gargouri, Raja .
CANCER SCIENCE, 2009, 100 (11) :2034-2039
[7]   Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type [J].
Foo, KF ;
Tan, EH ;
Leong, SS ;
Wee, JTS ;
Tan, T ;
Fong, KW ;
Koh, L ;
Tai, BC ;
Lian, LG ;
Machin, D .
ANNALS OF ONCOLOGY, 2002, 13 (01) :150-156
[8]   Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials [J].
Fritsch, Christine ;
Huang, Alan ;
Chatenay-Rivauday, Christian ;
Schnell, Christian ;
Reddy, Anupama ;
Liu, Manway ;
Kauffmann, Audrey ;
Guthy, Daniel ;
Erdmann, Dirk ;
De Pover, Alain ;
Furet, Pascal ;
Gao, Hui ;
Ferretti, Stephane ;
Wang, Youzhen ;
Trappe, Joerg ;
Brachmann, Saskia M. ;
Maira, Sauveur-Michel ;
Wilson, Christopher ;
Boehm, Markus ;
Garcia-Echeverria, Carlos ;
Chene, Patrick ;
Wiesmann, Marion ;
Cozens, Robert ;
Lehar, Joseph ;
Schlegel, Robert ;
Caravatti, Giorgio ;
Hofmann, Francesco ;
Sellers, William R. .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) :1117-1129
[9]  
Hui ABY, 2002, INT J ONCOL, V20, P467
[10]   Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation [J].
Hui, E. P. ;
Ma, B. B. Y. ;
King, A. D. ;
Mo, F. ;
Chan, S. L. ;
Kam, M. K. M. ;
Loong, H. H. ;
Ahuja, A. T. ;
Zee, B. C. Y. ;
Chan, A. T. C. .
ANNALS OF ONCOLOGY, 2011, 22 (06) :1280-1287